Result Analysis: Sun Pharmaceutical Ltd. Result Update Q2FY22
Particulars (In ₹. Cr) Q2FY22 Q1FY22 Q2FY21 QoQ % YoY%
Revenue from Operation 9625.9 9718.7 8553.1 -0.95% 12.54%
Other Income 222.8 152.5 255.7 46.10% -12.87%
Total Income 9848.7 9871.2 8808.8 -0.23% 11.81%
Material cost 1584.9 1562.1 1459.8 1.46% 8.57%
Other Expenses 5977.4 5873.8 5431.9 1.76% 10.04%
Material cost as percentage of Total Income 16.46% 16.07% 17.07% 2.44% -3.53%
EBITDA 2630 2,772 2192 -5.12% 19.98%
EBITDA Margin 27.32% 28.52% 25.63% -4.20% 6.61%
Profit After Tax 2,047.00 1,444.17 1,812.79 41.74% 12.92%
PATM (%) 21.27% 14.86% 21.19% 43.11% 0.34%
Basic EPS (in Rs. ) 8.5 6 7.6 41.67% 11.84%
Geographical Revenue Q2FY22 Q1FY22 Q2FY21 QoQ % YoY%
India Formulation 3187.8 3308.3 2531.1 -3.64% 25.95%
US Formulation 2677.3 2800 2491.5 -4.38% 7.46%
Emerging Market 1800.5 1605.2 1558.7 12.17% 15.51%
ROW Formulation 1392.6 1368 1336.28 1.80% 4.21%
Bulk 435.8 514.8 510.4 -15.35% -14.62%
Others 62.6 72.9 46.5 -14.13% 34.62%

Result Highlight: 

  • Sun Pharma Revenue was flat QoQ and rose 12.54% YoY to ₹ 9625 crore – better than the estimates of ₹ 8980 Crore. Other income fall87% YoY to ₹ 222.8 Crore.

  • Company reported EBITDA of ₹ 2630 crore vs ₹2192 crore same quarter last year Margin was flat at 32% from 28.52% last quarter.

  • Net profit rose 12.92% YoY to ₹2047 crore for the September quarter compared with ₹ 1812 crore in the same  quarter last

  • The company reported strong operating Cash flow of ₹ 4027 Crore and free cash flow of ₹3046 crore in Q2 FY22.

  • In US Market Company register a growth of 7.46% Y-o-Y.

  • Sun subsidiary Taro Pharmaceuticals resolved all matters in connection with the multi-year investigations by the Department of Justice, Antitrust Division and Civil Division (“DOJ”) into the United States generic pharmaceutical industry.

  • Dusa Pharmaceuticals, Inc. reached an agreement with the U.S. Department of Justice and an individual to resolve allegations relating to the sales, marketing and promotion of two of its products – Levulan and Blu-u, as extension of a Civil Investigation Demand for the period January 2010 to September 2017. The Company had made a provision of ₹1,563.6 Million for this settlement during the year ended March 31, 2020.

  • Taro posted Q2FY22 sales of US$ 132 million, lower by about 8% YoY and adjusted net profit of about US$ 25 million, lower by 45% over Q2 last year.

  • Consolidated R&D investment for Q2FY22 was ₹ 536 crore as compared to ₹ 612.7 crore for Q2 last year. The reduction is due to spill-over of certain clinical studies into subsequent quarters. For the first half, R&D expense was ₹1129 crore, or 5.9% of sales.

Management commentary: 

Dilip Shanghvi, Managing Director of the Company said, “Following our good Q1 performance, we have sustained the positive momentum in Q2 with a topline growth of 13% YoY, driven by a broad-based growth across multiple geographies. Our global specialty business has grown by 43% over Q2 last year. Ilumya has grown both YoY and sequentially. Our India business continues to do well with a growth of 26% YoY. We remain steadfast in our focus on growing our overall business and simultaneously strengthening our global specialty portfolio. The recent launch of Winlevi in US and Ilumya in Canada is a step forward in this direction.

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited,
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting, or emailing with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website:
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL